Medication Adherence in Inflammatory Bowel Disease

Overview

Journal Intest Res

Date 2017 Nov 17

PMID 29142511

Citations 74

Authors

Webber Chan

Andy Chen

Darren Tiao

Christian Selinger

Rupert Leong

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition with intestinal and extraintestinal manifestations. Medications are the cornerstone of treatment of IBD. However, patients often adhere to medication poorly. Adherence to medications is defined as the process by which patients take their medications as prescribed. Treatment non-adherence is a common problem among chronic diseases, averaging 50% in developed countries and is even poorer in developing countries. In this review, we will examine the adherence data in IBD which vary greatly depending on the study population, route of administration, and methods of adherence measurement used. We will also discuss the adverse clinical outcomes related to non-adherence to medical treatment including increased disease activity, flares, loss of response to anti-tumor necrosis factor therapy, and so forth. There are many methods to measure medication adherence namely direct and indirect methods, each with their advantages and drawbacks. Finally, we will explore different intervention strategies to improve adherence to medications.

Citing Articles

Medication Non-Adherence in Inflammatory Bowel Disease: A Systematic Review Identifying Risk Factors and Opportunities for Intervention.

King K, Czuber-Dochan W, Chalder T, Norton C Pharmacy (Basel). 2025; 13(1).

PMID: 39998019 PMC: 11859822. DOI: 10.3390/pharmacy13010021.

Interprofessional approach to personalized medication management and therapy optimization in IBD care.

Fleischmann D, Binder B, Huss M, Elger T, Wolf C, Loibl J Front Med (Lausanne). 2025; 12:1446695.

PMID: 39944491 PMC: 11814462. DOI: 10.3389/fmed.2025.1446695.

Designing for medication adherence in inflammatory bowel disease: multi-disciplinary approaches for self-administrable biotherapeutics.

Feig V, Zhang S, Patel A, Santos B, Kang Z, Wasan S EClinicalMedicine. 2025; 77:102850.

PMID: 39763512 PMC: 11701474. DOI: 10.1016/j.eclinm.2024.102850.

Obstacles to Medication Adherence for Patients with Inflammatory Bowel Disease: A Qualitative Study in East China.

Xu F, Xing J, Fan M, Zhu Z, Chen Y, Hu W Patient Prefer Adherence. 2024; 18:2481-2494.

PMID: 39669315 PMC: 11635160. DOI: 10.2147/PPA.S486974.

Prediction of the Short-Term Effectiveness of Ustekinumab in Patients with Moderate to Severe Crohn's Disease.

Su T, Liu L, Meng F, Wu H, Liu T, Deng J J Inflamm Res. 2024; 17:9181-9191.

PMID: 39588135 PMC: 11586492. DOI: 10.2147/JIR.S479618.

References

Horne R, Parham R, Driscoll R, Robinson A . Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 15(6):837-44. DOI: 10.1002/ibd.20846. View

Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B . E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut. 2010; 59(12):1652-61. DOI: 10.1136/gut.2010.220160. View

van der Have M, Oldenburg B, Kaptein A, Jansen J, Scheffer R, van Tuyl B . Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. J Crohns Colitis. 2016; 10(5):549-55. PMC: 4957450. DOI: 10.1093/ecco-jcc/jjw002. View

Fenerty S, West C, Davis S, Kaplan S, Feldman S . The effect of reminder systems on patients' adherence to treatment. Patient Prefer Adherence. 2012; 6:127-35. PMC: 3287416. DOI: 10.2147/PPA.S26314. View

Cuffari C, Hunt S, Bayless T . Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001; 48(5):642-6. PMC: 1728278. DOI: 10.1136/gut.48.5.642. View

Kane S, Becker B, Harmsen W, Kurian A, Morisky D, Zinsmeister A . Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012; 107(2):154-60. DOI: 10.1038/ajg.2011.317. View

Cross R, Cheevers N, Rustgi A, Langenberg P, Finkelstein J . Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis. 2011; 18(6):1018-25. PMC: 3179574. DOI: 10.1002/ibd.21795. View

Hommel K, Herzer M, Ingerski L, Hente E, Denson L . Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr. 2011; 53(4):435-9. PMC: 3674887. DOI: 10.1097/MPG.0b013e3182203a91. View

Suzuki Y, Iida M, Ito H, Nishino H, Ohmori T, Arai T . 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial. Inflamm Bowel Dis. 2017; 23(5):822-832. PMC: 5404402. DOI: 10.1097/MIB.0000000000001065. View

10.

Jackson C, Clatworthy J, Robinson A, Horne R . Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2009; 105(3):525-39. DOI: 10.1038/ajg.2009.685. View

11.

Morisky D, Malotte C, Choi P, Davidson P, Rigler S, Sugland B . A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q. 1990; 17(3):253-67. DOI: 10.1177/109019819001700303. View

12.

Moss A, Lillis Y, Edwards George J, Choudhry N, Berg A, Cheifetz A . Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014; 109(12):1850-5. DOI: 10.1038/ajg.2014.158. View

13.

Balkrishnan R . The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care. 2005; 43(6):517-20. DOI: 10.1097/01.mlr.0000166617.68751.5f. View

14.

Waters B, Jensen L, Fedorak R . Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005; 19(4):235-44. DOI: 10.1155/2005/250504. View

15.

Morisky D, DiMatteo M . Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol. 2010; 64(3):255-7. PMC: 3109729. DOI: 10.1016/j.jclinepi.2010.09.002. View

16.

Trindade A, Ehrlich A, Kornbluth A, Ullman T . Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2010; 17(2):599-604. DOI: 10.1002/ibd.21310. View

17.

Cook P, Emiliozzi S, El-Hajj D, McCabe M . Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ Couns. 2010; 81(2):182-6. DOI: 10.1016/j.pec.2009.12.010. View

18.

Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L . Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013; 19(7):1528-33. DOI: 10.1097/MIB.0b013e31828132cb. View

19.

Kim S, Kim K, Jang B, Kim E, Cho K, Park K . Patients' beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. J Gastroenterol Hepatol. 2015; 31(3):575-80. DOI: 10.1111/jgh.13155. View

20.

Brooks A, Begg E, Zhang M, Frampton C, Barclay M . Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit. 2007; 29(5):619-25. DOI: 10.1097/FTD.0b013e31811f39bb. View